KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Waters, Andrew M., Der, Channing J.·2018·Cold Spring Harbor Perspectives in Medicine
DOI 10.1101/cshperspect.a031435

Cited by (882)

Items 401–500 of 882

  1. Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
    Zhaoyong Han, Ding Zhou, JiaMan Wang, Bruce Jiang, XiYu Liu · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  2. DNA Polymerase Theta Plays a Critical Role in Pancreatic Cancer Development and Metastasis
    Agnieszka Smolinska, Kerstin Singer, Janine Golchert, Urszula Smyczyńska, Wojciech M Fendler, Matthias Sendler, Jens van den Brandt, Stephan Singer, Georg Homuth, Markus M. Lerch et al. · 2022 · Cancers
  3. Actin Waves and Dynamic Patterning of the Plasma Membrane.
    Guenther Gerisch, Jana Prassler, Nelson Butterfield, Mary Ecke · 2019 · Europe PMC (PubMed Central)
  4. An Organotypic Microcosm for the Pancreatic Tumor Microenvironment
    Miranda Lin, Mei Gao, Prakash Krishnan Pandalai, Michael J. Cavnar, Joseph Kim · 2020 · Cancers
  5. RETRACTED ARTICLE: Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment
    Fengyong Wang, Zhen Zhang · 2020 · Pharmaceutical Research · Retracted
  6. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC
    Olamide Tosin Olaoba, Funmilayo C. Ligali, Zaccheaus O. Alabi, Amos Olalekan Akinyemi, Kehinde Sulaimon Ayinde · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  7. Comorbidity network analysis and genetics of colorectal cancer
    Branimir Ljubic, Martin Pavlovski, Jumanah S. Alshehri, Shoumik Roychoudhury, Vladimir B. Bajić, Christophe Van Neste, Zoran Obradovic A · 2020 · Informatics in Medicine Unlocked
  8. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
    Bach Ardalan, Jose Ignacio Azqueta, Jonathan S. England, Tiffany Alyssa Eatz · 2021 · Molecular Case Studies
  9. The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells
    Meiyan Chen, Meiyan Chen, Yuka Fu, Jingyi Zhang · 2023 · Pathology - Research and Practice
  10. Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
    Prashanth Ashok Kumar, Serenella Serinelli, Daniel J. Zaccarini, Richard S.P. Huang, Natalie A. Danziger, Tyler Janovitz, Alina Basnet, Abirami Sivapiragasam, Stephen L. Graziano, Jeffrey S. Ross · 2023 · Frontiers in Oncology
  11. Insights into curcumin’s anticancer activity in pancreatic ductal adenocarcinoma: Experimental and computational evidence targeting HRAS, CCND1, EGFR and AKT1
    Jun‐Feng Cao, Xiao Zhang, Qingjie Xia, Kuan Hang, Jie Men, Jinbin Tian, Dunshui Liao, Zengliang Xia, Kezhou Li · 2025 · Bioorganic Chemistry
  12. Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery
    Rabin Neupane, Saloni Malla, Chandrabose Karthikeyan, Charles R. Asbhy, Sai H. S. Boddu, Ramapuram Jayachandra Babu, Amit Kumar Tiwari · 2025 · International Journal of Pharmaceutics
  13. Pancreatic Steatosis as a Risk Factor for Pancreatic Ductal Adenocarcinoma: Pathogenesis and Clinical Implications
    Zoi Papalamprakopoulou, Prasenjit Dey, Rachel Frascati, Christos K Fountzilas · 2025 · Clinical and Translational Gastroenterology
  14. Epithelial-mesenchymal transition and H2O2 signaling – a driver of disease progression and a vulnerability in cancers
    Anna V. Milton, David Benjamin Konrad · 2022 · Biological Chemistry
  15. The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells
    Chitra Palanivel, Neha Chaudhary, Parthasarathy Seshacharyulu, Jesse L. Cox, Ying Yan, Surinder K. Batra, Michel M. Ouellette · 2022 · Neoplasia
  16. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells
    Shaw M. Akula, Saverio Candido, Stephen Lee Abrams, Linda S. Steelman, Kvin Lertpiriyapong, Lucio Cocco, Giulia Ramazzotti, Stefano Ratti, Matilde Y. Follo, Alberto Maria Martelli et al. · 2019 · Advances in Biological Regulation
  17. Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor
    Manoj Amrutkar, Emma Kristine Larsen, Monica Aasrum, Anette Vefferstad Finstadsveen, Per Arne Andresen, Caroline Sophie Verbeke, Ivar P. Gladhaug · 2020 · Cells
  18. Design and Efficient Synthesis of RalA Inhibitors Containing the Dihydro‐α‐carboline Scaffold
    Hai‐Jun Leng, Yuting Wang, Xiang‐Hong He, Houlin Xia, Peng‐Shuai Xu, Peng Xiang, Qingqing He, Gu Zhan, Wei Huang · 2020 · ChemMedChem
  19. The current state of molecular profiling in gastrointestinal malignancies
    Reetu Mukherji, Chao Yin, Rumaisa Hameed, Ali Jaber Alqahtani, Monika Kulasekaran, Aiwu Ruth He, Benjamin Adam Weinberg, John Lindsay Marshall, Marion L. Hartley, Marcus Smith Noel · 2022 · Biology Direct
  20. KRAS, a New Target for Precision Medicine in Colorectal Cancer?
    Boilève, Alice, Smolenschi, Cristina, Lambert, Aurélien, Boige, Valérie, Delaye, Matthieu, Camilleri, Géraldine M., Tarabay, Anthony, Valéry, Marine, Fuerea, Alina, Pudlarz, Thomas et al. · 2024 · Cancers
  21. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer
    Zhaojuan Liu, Heping Zheng, Yanqing Tian, Zhuoyue Li, Sai Zhang, Siqi Zhang, Shumin Ma, Xiao Wang, Chong Qin · 2025 · Journal of Medicinal Chemistry
  22. Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
    Hiroki Ozawa, Keiko Takahashi, Tomoki Motegi, Justine J. Jacobi, Atrayee Bhattacharya, Keisuke Shigeta, Shinkichi Takamori, Mai Onishi, Zhou Luan, Kazumasa Fukuda et al. · 2025 · Clinical Cancer Research
  23. Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models
    Lisa M. Nilsson, Caroline Vilhav, Joakim W. Karlsson, Johan Bourghardt Fagman, Daniel Giglio, Cecilia Engström, Peter L. J. Naredi, Jonas A. Nilsson · 2022 · Gastro Hep Advances
  24. UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect
    Emily G. Caggiano, Cullen M. Taniguchi · 2024 · Cancer and Metastasis Reviews
  25. Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome
    William A. Preston, Esther N Drill, Thomas Boerner, Rebecca Gelfer, James J. Harding, Eileen Mary O'Reilly, Andrea Cercek, Ghassan K. Abou‐Alfa, Wungki Park, Vinod P. Balachandran et al. · 2024 · JCO Precision Oncology
  26. Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinoma
    Fan Meng, Tiane Li, Anup Kumar Singh, Yingying Wang, Marc A. Attiyeh, Fatemeh Kohram, Qianhua Feng, Yun R. Li, Binghui Shen, Terence Marques Williams et al. · 2024 · Cell Reports
  27. Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5
    Jiali Gong, Xiawei Li, Zengyu Feng, Jianyao Lou, Kaiyue Pu, Yongji Sun, Sien Hu, Yizhao Zhou, Tianyu Song, Meihua Shangguan et al. · 2024 · Experimental & Molecular Medicine
  28. Predicting Pancreatic Cancer in New‐Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large‐Scale Prospective Cohort Study
    Yongji Sun, Chaolu Hu, Sien Hu, Hongxia Xu, Jiali Gong, Yixuan Wu, Yiqun Fan, Changming Lv, Tianyu Song, Jianyao Lou et al. · 2024 · Cancer Medicine
  29. Distinct forms of the actin cross-linking protein α-actinin support macropinosome internalization and trafficking
    Kevin M. Burton, Katherine M. Johnson, Eugene W. Krueger, Gina L. Razidlo, Mark A. McNiven · 2021 · Molecular Biology of the Cell
  30. A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma
    Zhigang Chen, Yun Wang, William Pat Fong, Ming-tao Hu, Jie‐Ying Liang, Lingyun Wang, Yuhong Li · 2021 · International Immunopharmacology
  31. Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks
    Guillermo Urrutia, Thiago M. de Assuncao, Angela Mathison, Ann Salmonson, Romica Kerketta, Atefeh Zeighami, Timothy J. Stodola, Volkan N. Adsay, Burçin Pehlivanoğlu, Michael B. Dwinell et al. · 2021 · Frontiers in Cell and Developmental Biology
  32. Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype
    Heléne Lindholm, Katarina Ejeskär, Ferenc L. M. Szekeres · 2022 · International Journal of Molecular Sciences
  33. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies
    James Andrew McCubrey, Stephen Lee Abrams, Matilde Y. Follo, Lucia Manzoli, Stefano Ratti, Alberto Maria Martelli, Melchiorre Cervello · 2022 · Advances in Biological Regulation
  34. Malian children infected with Plasmodium ovale and Plasmodium falciparum display very similar gene expression profiles
    Kieran Tebben, Salif Yirampo, Drissa Moriba Coulibaly, Abdoulaye Kassoum Kone, Matthew Brent Laurens, Emily M. Stucke, Ahmadou Dembélé, Youssouf Tolo, Karim Traoré, Amadou Niangaly et al. · 2023 · PLoS neglected tropical diseases
  35. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
    Jordi Ahnert Rodon, Daniel Shao-Weng Tan, Ignacio Garrido‐Laguna, Wael A. Harb, Alberto Bessudo, Joseph Thaddeus Beck, Sylvie Rottey, Nathan Bahary, Nuria Kotecki, Z. Zhu et al. · 2023 · ESMO Open
  36. Carboxypeptidase E-∆N Promotes Proliferation and Invasion of Pancreatic Cancer Cells via Upregulation of CXCR2 Gene Expression
    Sangeetha Hareendran, Xu-Yu Yang, Hong Lou, Lan Xiao, Y. Peng Loh · 2019 · International Journal of Molecular Sciences
  37. Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors
    Zheng Zhao, Tao Fu, Jiyue Gao, Yang Xu, Xue Wu, Wenjuan Chen, Xuesong Li, Ruoying Yu, Yang Washington Shao, Man Li et al. · 2020 · Journal of Medical Genetics
  38. Interaction between RAS gene and lipid metabolism in cancer
    Mingquan Zhang, Junchen Pan, Peng Huang · 2021 · Journal of Zhejiang University (Medical Sciences)
  39. A Ductal-Cell-Related Risk Model Integrating Single-Cell and Bulk Sequencing Data Predicts the Prognosis of Patients With Pancreatic Adenocarcinoma
    Xitao Wang, Xiaolin Dou, Xinxin Ren, Zhuoxian Rong, Lun‐Quan Sun, Yuezhen Deng, Pan Chen, Zhi Li · 2022 · Frontiers in Genetics
  40. Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment
    Abdul Rashid Issahaku, Elliasu Yakubu Salifu, Mahmoud E. S. Soliman · 2022 · Journal of Biomolecular Structure and Dynamics
  41. Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
    Liang Zhu, Jun‐Tao Ji, Jianjia Ma, Dan Wang, Muyun Liu, James Xianxing Du, Rong Chen, Wei Hou, James L. Abbruzzese, Craig D. Logsdon et al. · 2022 · Cancers
  42. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
    Jonathan M. DeLiberty, Ryan N. Robb, Claire E. Gates, Kirsten L. Bryant · 2022 · Advances in cancer research
  43. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer
    Ye S. Lee, Jennifer E. Klomp, Clint A. Stalnecker, Craig M. Goodwin, Yanzhe Gao, Gaith N. Droby, Cyrus Vaziri, Kirsten L. Bryant, Channing J. Der, Adrienne D. Cox · 2023 · Genes & Cancer
  44. Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
    Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Xiaoming Ren, Wei Huang, Teng Feng, Lili Yao, Jing Lin et al. · 2024 · Molecular Cancer Therapeutics
  45. Targeting KRAS in gynecological malignancies
    Yuanyuan Peng, Qing fan Yang · 2024 · The FASEB Journal
  46. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients
    Xiongfei Xu, Shiwei Guo, Haihui Gu, Zhanshan Cha, Xiaohan Shi, Xiaoyi Yin, Huan Wang, Suizhi Gao, Bo Li, Lingyu Zhu et al. · 2025 · JCI Insight
  47. Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients
    Andrea N. Riner, Enrique I. Velazquez-Villarreal, Seeta Rajpara, Jing Qian, Yuxin Jin, Donna Loza, Ashwin S. Akki, Kelly M. Herremans, Rohit Raj, Terence Marques Williams et al. · 2025 · Pancreas
  48. Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma
    M.C. Cox, Dominic J. Vitello, Akhil Chawla · 2025 · Frontiers in Oncology
  49. The role of inflammatory factors in the tumor microenvironment of pancreatic cancer
    Yuzhang Yuan, Haozhe Zhang, Zehua Wang, Luying Huang, Derya Kabacaoğlu, Boxing Zhang, Liang Song, Jiaoyu Ai · 2025 · Frontiers in Immunology
  50. Modulation of Fibroblast Phenotype by Colorectal Cancer Cell-Secreted Factors Is Mostly Independent of Oncogenic KRAS
    Patrícia Dias Carvalho, Susana Mendonça, Flávia Martins, María José Oliveira, Sérgia Velho · 2022 · Cells
  51. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach
    S. Udhaya Kumar, Rinku Polachirakkal Varghese, V. Anu Preethi, C. George Priya Doss, Hatem Zayed · 2023 · Frontiers in Bioscience-Landmark
  52. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response
    Arian Ansardamavandi, Mehrdad Nikfarjam, Hong Zhen He · 2023 · Cells
  53. Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells
    Eros Di Giorgio, Himanshi Choudhary, Annalisa Ferino, Ylenia Cortolezzis, Emiliano Dalla, Francesca D’Este, Marina Comelli, Valentina Rapozzi, Luigi Emilio Xodo · 2023 · iScience
  54. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma
    Miquel S. Porta, José A. Pumarega, André F.S. Amaral, Jeanine M. Genkinger, Judit Camargo, Lorelei Ann Mucci, Juan Alguacil, Magda Gasull, Xuehong Zhang, Eva Morales et al. · 2020 · Environmental Research
  55. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions
    Reecha Suri, Jacquelyn W. Zimmerman, Richard Andrew Burkhart · 2020 · Annals of Pancreatic Cancer
  56. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53
    Stephen Lee Abrams, Shaw M. Akula, Linda S. Steelman, Matilde L. Follo, Lucio Cocco, Stefano Ratti, Alberto Maria Martelli, Massimo Libra, Luca Falzone, Saverio Candido et al. · 2021 · Advances in Biological Regulation
  57. Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head
    Sami Alexander Safi, Lena Häberle, Wolfgang Goering, Verena Keitel, Georg Fluegen, Nikolas Hendrik Stoecklein, Alexander Rehders, Wolfram Trudo Knoefel, Iréne Esposito · 2022 · Cancers
  58. Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
    Ahmad Hassan Ali, Ugo Chianese, Chiara Papulino, Antonella Toraldo, Mawada Elmagboul Abdalla Abakar, Eugenia Passaro, Rosario Cennamo, Nunzio Del Gaudio, Lucia Altucci, Rosaria Benedetti · 2022 · Cancers
  59. Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis
    Sandeep Nadella, Julian Burks, Matthew Huber, Juan Wang, Hong Cao, Bhaskar Kallakury, Robin D. Tucker, Simina Maria Boca, Ashley A. Jermusyk, Irene J. Collins et al. · 2019 · Pancreas
  60. Identification of a C3′-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth
    Marc-Olivier Labbé, Laura Collins, Carole-Anne Lefebvre, Wael M. Maharsy, Janie Beauregard, Starr Dostie, Michel Prévost, Mona J. Nemer, Yvan Guindon · 2020 · Bioorganic & Medicinal Chemistry Letters
  61. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
    Urszula N. Wasko, Jingjing Jiang, Álvaro Curiel‐García, Yingyun Wang, Bianca J. Lee, Margo Orlen, Kristina Drizyte‐Miller, Marie J. Menard, Julien Dilly, Stephen A. Sastra et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  62. Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
    Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani · 2025 · Cancers
  63. CAR T cells based on fully human T cell receptor–mimetic antibodies exhibit potent antitumor activity in vivo
    Robert R. Salzler, David J. DiLillo, Kei Saotome, Kevin Bray, Katja Mohrs, Haun Hwang, Kamil J. Cygan, Darshit Shah, Anna Rye-Weller, Kunal Kundu et al. · 2025 · Science Translational Medicine
  64. Targeting and exploiting macropinocytosis in cancer therapy
    Hye‐ran Moon, Bo Kyung Cho, Seung Hyun Kang, Ju Hee Ryu, Ick Chan Kwon · 2025 · Journal of Controlled Release
  65. Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction
    Saumya Dushyant Sisoudiya, Hanna Tukachinsky, Rachel B. Keller-Evans, Alexa Betzig Schrock, Richard S.P. Huang, Ole V. Gjoerup, Michael J. Pishvaian, Rachna T. Shroff, Ethan S. Sokol, Lucas M. Dennis et al. · 2025 · npj Precision Oncology
  66. KRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutants
    Eunhye Jeon, Chan Kim, Minjoo Ko, Taeyul K. Kim, Juhyeon Bae, Jae Won Oh, Kwang Pyo Kim, Han Sang Kim, Taebo Sim · 2025 · European Journal of Medicinal Chemistry
  67. Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
    Yogitha S. Chareddy, Hayden P. Huggins, Snehasudha S Sahoo, Lyla J. Stanland, Christina Gutierrez-Ford, Kristina Marinak Whately, Lincy Edatt, Salma H. Azam, Matthew C. Fleming, Jonah Im et al. · 2025 · Journal of Clinical Investigation
  68. Hydrophobic tagging: A promising paradigm for targeted protein degradation
    Li-Lan Xin, Hongli Wang, Mao Yang, Zhangxiao Guo, Man Zhu, Terry W. Moore, Chu-Ne Dong, Hai-Bing Zhou · 2025 · Cell Insight
  69. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
    Jiujie Cui, Kuirong Jiang, Wei Li, Shuqin Ni, Hong Zong, Juan Du, Yifu He, Zhonghua Liu, Guoqiang Kong, Yu Zhang et al. · 2026 · Nature Medicine
  70. Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis
    Lisa Fahr, Yoshiaki Sunami, Nadja Maeritz, Katja Steiger, Thomas G. P. Grünewald, Martin T. Gericke, Bo Kong, Susanne Raulefs, Julia V. Mayerle, Christoph W. Michalski et al. · 2020 · Pancreatology
  71. Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins
    Vinay V. Nair, Guowei Yin, Jerry Zhang, John F. Hancock, Sharon L. Campbell, Alemayehu Abebe Gorfe · 2021 · The Journal of Physical Chemistry B
  72. Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties
    Valentina Audrito, Enrico Moiso, Filippo Ugolini, Vincenzo Gianluca Messana, Lorenzo Brandimarte, Ilaria Manfredonia, Simonetta Bianchi, Francesco De Logu, Romina Nassini, Anna Szumera‐Ciećkiewicz et al. · 2022 · Journal of Translational Medicine
  73. Involvement of FAM83 Family Proteins in the Development of Solid Tumors: An Update Review
    Yi Wei Jiang, Jiahui Yu, Tong Zhu, Jiawen Bu, Yueting Hu, Yang Liu, Xudong Zhu, Xi Gu · 2023 · Journal of Cancer
  74. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma
    Yan Qin Tan, Bowen Sun, Xi Zhang, Shuwei Zhang, Hui Guo, Basappa Basappa, Tao Zhu, Gautam Sethi, Peter Edward Lobie, Vijay Pandey · 2024 · Cell Death and Disease
  75. Screening Metabolic Biomarkers in KRAS Mutated Mouse Acinar and Human Pancreatic Cancer Cells via Single-Cell Mass Spectrometry
    Qinlei Liu, Jiayi Lan, Sandra Martínez‐Jarquín, Wenjie Ge, Renato Zenobi · 2024 · Analytical Chemistry
  76. Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases
    Geou‐Yarh Liou, Crystal J. Byrd, Peter Störz, Justin K. Messex · 2024 · International Journal of Molecular Sciences
  77. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets
    Emilia Alors‐Pérez, Ricardo Blázquez‐Encinas, María Trinidad Moreno-Montilla, Víctor García‐Vioque, Juan M. Jiménez‐Vacas, Andrea Mafficini, Iranzu González‐Borja, Claudio Luchini, Juan Manuel Sánchez‐Hidalgo, Marina Sánchez‐Frías et al. · 2024 · Molecular Oncology
  78. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges
    Yuting Shao, Li Ma, Tiehui Zhang, Tian‐Rui Xu, Yuanchao Ye, Ying Liu · 2019 · Current Topics in Medicinal Chemistry
  79. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer
    Yixing Wu, Huatian Huang, Béatrice Fervers, Lingeng Lu · 2020 · Pancreas
  80. Fluorinated thiazolidinol drives autophagic cell death in pancreatic cancer cells via AMPK activation and perturbation of critical sentinels of oncogenic signaling
    Dinesh Kumar, Vamsi Krishna Kommalapati, Mahesh Kumar Jerald, Anjana Devi Tangutur · 2021 · Chemico-Biological Interactions
  81. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma
    Hannah Pook, Siim Pauklin · 2021 · Cancers
  82. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
    Seyed Saeed Pairawan, Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Q. Rizvi, Vijaykumar R. Holla, Jing Wang et al. · 2022 · Scientific Reports
  83. APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
    James Andrew McCubrey, Stephen Lee Abrams, Linda S. Steelman, Lucio Cocco, Stefano Ratti, Alberto Maria Martelli, Paolo Lombardi, Agnieszka Gizak, Przemysław Duda · 2022 · Biomolecules
  84. The Functional Role of LncRNA UCA1 in Pancreatic Cancer: a mini-review
    Cen-Cen Sun, Li Li, Zhichen Jiang, Zhengchuang Liu, Liang Wang, Hui‐Ju Wang · 2023 · Journal of Cancer
  85. The discovery of some promising putative binders of KRAS G12D receptor using computer-aided drug discovery approach
    Abdul-Quddus Kehinde Oyedele, Nurudeen Owolabi, Tope Tunji Odunitan, Abosede Christiana Ajibare, Rukayat Olajumoke Jimoh, Waliu O. Abdulazeez, Maryam Bello-Hassan Titilayo, Abiola Sarah Soares, Adedayo Toluwani Adekola, Teslim Oluwaseyi Abdulkareem et al. · 2023 · Informatics in Medicine Unlocked
  86. Diabetes and Cancer: The Epidemiological and Metabolic Associations
    Cissy Zhang, Anne Le · 2021 · Advances in experimental medicine and biology
  87. An Emerging Role of KRAS in Biogenesis, Cargo Sorting and Uptake of Cancer-Derived Extracellular Vesicles
    Zhijack Fong, Wai-Leng Lee · 2022 · Future Medicinal Chemistry
  88. Knockdown of UBQLN1 Functions as a Strategy to Inhibit CRC Progression through the ERK-c-Myc Pathway
    Ruoxuan Ni, Jianwei Jiang, Mei Zhao, Shengkai Huang, Changzhi Huang · 2023 · Cancers
  89. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
    Dakota W. Goad, Anna Y. Nesmelova, Laurel R. Yohe, Valery Z. Grdzelishvili · 2023 · Journal of Virology
  90. A novel and promising therapeutic approach for treating pancreatic cancer: Nectin‑4‑targeted antibody‑drug conjugates alone or combined with autophagy inhibitors
    Rong Fu, Chunbin Wang, Tongjin Yin, Xuyao Zhang, Ying Xu, Yue Shi, Jing Xu, Wei Zhang, Zhe Ding · 2025 · International Journal of Molecular Medicine
  91. Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers
    Yelixza I. Avila, Anh Thu Ha, Morgan R. Chandler, Nathalia Leal Santos, Tae‐Jin Kim, Hannah S. Newton, Marina A. Dobrovolskaia, Kirill A. Afonin · 2025 · Advanced Functional Materials
  92. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer
    Priya S. Hibshman, Clint A. Stalnecker, Jeffrey A. Klomp, Kristina Drizyte‐Miller, Jennifer E. Klomp, A. Cole Edwards, Lily M. Pita, Richard G. Hodge, J. Nathaniel Diehl, Ryan D. Mouery et al. · 2025 · Science Signaling
  93. Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions
    Ahmed Bendari, Oana E. Vele, Brett W. Baskovich, Alaa Bendari, Mona Sebika, Juan Luis Gomez Marti, Kritika Krishnamurthy, Saeed Asiry · 2025 · Gastroenterology Insights
  94. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
    Xiongfei Xu, Haihui Gu, Zhanshan Cha, Bin Zhang, Shuai Yuan, Xiuwen Ding, Lei Gao, Suizhi Gao, Xinqian Wu, Lingyun Gu et al. · 2026 · Molecular Therapy
  95. The Emerging Scenario of Ferroptosis in Pancreatic Cancer Tumorigenesis and Treatment
    Hao Lyu, Jinghua Kong, Jiasi Chen, Rui Zhang, Shuai Xiao, Dong Sheng Guo, Qi Zhang, Xing‐Zhen Chen, Jingfeng Tang, Cefan Zhou · 2024 · International Journal of Molecular Sciences
  96. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
    Ashleigh Parkin, Jennifer Man, Angela S. Y. Chou, Adnan M. Nagrial, Jaswinder Singh Samra, Anthony James Gill, Paul Timpson, Marina Pajic · 2018 · Diseases
  97. Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine
    Chung-Tsui Huang, Yao‐Jen Liang · 2021 · World Journal of Clinical Cases
  98. QKI-Regulated Alternative Splicing Events in Cervical Cancer: Pivotal Mechanism and Potential Therapeutic Strategy
    Yalan Luo, Yuyuan Li, Peng Ge, Kaina Zhang, Huanhuan Liu, Nan Jiang · 2021 · DNA and Cell Biology
  99. Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients
    Sarah Owen, Emily R. Prantzalos, Valerie Gunchick, Vaibhav Sahai, Sunitha Nagrath · 2022 · Biomedicines
  100. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer
    Xiang Fei, Lingming Kong, Chao Shi, Gang Wang, Chenhai Liu, Cheng Wang, Peng Liu, Xiaodong Tan · 2022 · Journal of Oncology